According to Gram Research analysis, scientists discovered that the energy required for drugs to bind to vitamin D and retinoic acid receptors—not just how tightly they stick—determines whether the drug activates or blocks the receptor. For RARγ receptors, this energy-based approach clearly separated activating drugs from blocking drugs, suggesting that future medications could be designed more precisely by considering both binding energy and molecular shape changes rather than relying on binding strength alone.
Scientists have discovered how certain drugs that mimic vitamin D and retinoic acid (a form of vitamin A) can either turn on or turn off specific receptors in your body. Using advanced computer simulations and structural analysis, researchers found that these drugs work by changing the shape of proteins in your cells and affecting how much energy is needed for binding. This research helps explain why some drugs activate these receptors while others block them, which could lead to better treatments for skin conditions, immune disorders, and other health issues. The findings suggest that drug effectiveness depends not just on how tightly a drug sticks to its target, but also on how it reshapes the protein and influences the surrounding molecular environment.
Key Statistics
A 2026 computational study published in the Journal of Chemical Information and Modeling found that effective enthalpy (binding energy) is a more informative predictor of drug function than binding affinity alone, with clear agonist-antagonist separation demonstrated for RARγ receptors.
Research combining molecular dynamics simulations and crystal structure analysis showed that drug selectivity emerges from the interplay among ligand-binding energetics, interaction networks, and receptor conformational dynamics rather than from binding affinity alone.
The study determined new crystal structures for two drug molecules (AGN194310 and AGN205728) using advanced MicroED microscopy, providing structural validation that improved understanding of how different drugs position themselves within receptor binding sites.
The Quick Take
- What they studied: How synthetic drugs bind to two important cellular receptors (RARγ and VDR) and whether they activate or block these receptors based on their molecular structure and energy patterns.
- Who participated: This was a computational study analyzing laboratory-synthesized drug molecules and their interactions with human receptor proteins using computer simulations and structural analysis—no human or animal subjects were involved.
- Key finding: According to Gram Research analysis, the energy required for drugs to bind to receptors (called effective enthalpy) is a better predictor of whether a drug will activate or block the receptor than simply measuring how tightly it sticks. For RARγ receptors, this energy pattern clearly separated activating drugs from blocking drugs.
- What it means for you: This research could help pharmaceutical companies design better drugs for skin conditions, psoriasis, and immune disorders by understanding the molecular mechanics of how these drugs work. However, these are early-stage findings that need further testing in real-world applications before they change medical practice.
The Research Details
Researchers used advanced computer modeling techniques to study how different drugs interact with two important protein receptors in human cells. They created detailed 3D models of these receptors and simulated what happens when various drug molecules bind to them. The team measured the energy required for binding and tracked how the receptor’s shape changed when different drugs attached. They also used a specialized technique called MicroED (a type of electron microscopy) to determine the actual crystal structures of two specific drug molecules, which helped validate their computer predictions.
The study compared drugs that activate these receptors (agonists) with drugs that block them (antagonists). By analyzing the thermodynamic profiles—essentially the energy patterns and molecular interactions—the researchers could identify what makes a drug turn a receptor on versus off. This approach combined multiple analytical methods to build a comprehensive picture of how these molecular interactions work at the atomic level.
Understanding the molecular mechanics of how drugs interact with receptors is crucial for designing better medications. Rather than relying solely on trial-and-error drug discovery, this research provides a scientific framework for predicting how a drug will behave before it’s tested in the lab or clinic. This knowledge can accelerate drug development and help researchers create more targeted treatments with fewer side effects.
This is a computational chemistry study published in a peer-reviewed journal, which means it underwent expert review. The researchers used well-established molecular dynamics simulation techniques and validated their computer models with actual crystal structures. However, this is theoretical research conducted on isolated proteins in computer simulations, not studies in living cells or organisms. The findings provide mechanistic insights but require experimental validation in biological systems to confirm their real-world applicability.
What the Results Show
The research revealed that the energy required for drugs to bind to receptors (measured as effective enthalpy) is more informative than binding affinity alone when distinguishing between drugs that activate versus block receptors. For RARγ receptors, this energy-based approach clearly separated activating drugs from blocking drugs, showing a distinct pattern. For VDR receptors, the pattern was less clear but still showed a directional trend.
The study found that how tightly a drug sticks to a receptor (binding affinity) doesn’t tell the whole story. Two drugs might stick equally well, but one could activate the receptor while the other blocks it. The difference lies in how the drug reshapes a critical part of the receptor called helix 12 and how it influences the network of molecular interactions around the binding site.
The researchers also determined new crystal structures for two specific drug molecules (AGN194310 and AGN205728) using advanced microscopy techniques. These structures provided important reference points for understanding how different drugs position themselves within the receptor binding pocket and confirmed predictions from their computer simulations.
The analysis revealed that functional selectivity—whether a drug activates or blocks a receptor—emerges from the complex interplay between three factors: how much energy is released when the drug binds, the specific network of molecular interactions formed, and how the receptor’s shape changes in response. This means that designing selective drugs requires considering all three factors simultaneously, not just optimizing one property. The study also showed that the entropic contributions (disorder-related energy) play a role but are less predictive than the enthalpic (binding energy) patterns.
This research builds on decades of nuclear receptor biology by providing a more detailed mechanistic understanding of how drugs achieve functional selectivity. Previous studies showed that drug selectivity depends on more than just binding affinity, but the specific molecular mechanisms remained unclear. This work provides a quantitative framework for understanding those mechanisms, suggesting that thermodynamic profiling could become a standard tool in drug discovery alongside traditional binding assays.
This study analyzed drug-receptor interactions using computer simulations and isolated protein structures, not in living cells or organisms. The findings are most robust for RARγ receptors but less definitive for VDR receptors. The research doesn’t account for how these drugs behave in the complex environment of living tissue, where many other proteins and molecules influence drug action. Additionally, the study focused on a limited set of representative drugs, so the findings may not apply universally to all drugs targeting these receptors. Finally, the entropic (disorder-related) contributions were estimated indirectly rather than measured directly, which introduces some uncertainty in those calculations.
The Bottom Line
For pharmaceutical researchers: Use thermodynamic profiling (measuring binding energy patterns) alongside traditional binding affinity measurements when developing new drugs for these receptors. This dual approach may improve the success rate of identifying truly selective drugs. Confidence level: Moderate—this is a mechanistic study that provides a useful framework but requires validation in drug development pipelines. For patients: No direct changes to current treatment recommendations, as this is foundational research that will inform future drug development rather than changing existing medications.
Pharmaceutical researchers and drug developers working on treatments for psoriasis, eczema, immune disorders, and other conditions involving these receptors should find this research valuable. Dermatologists and immunologists may eventually benefit from better drugs developed using these insights. This research is not directly applicable to patients currently taking medications, but it could influence which new drugs are developed in the future.
This is early-stage mechanistic research. If these findings are validated and incorporated into drug development, it could take 5-10 years before new drugs based on these insights reach clinical trials, and another 5-10 years for FDA approval and market availability. The immediate impact will be on research laboratories rather than patient care.
Frequently Asked Questions
How do vitamin D drugs know whether to turn on or turn off my immune system?
Vitamin D receptor drugs work by changing the shape of the receptor protein and affecting how much energy is needed to bind. The specific energy pattern and molecular interactions determine whether the drug activates or blocks the receptor, rather than just how tightly it sticks. This research helps explain the molecular mechanism behind this selectivity.
Why is this research about drug molecules important for treating skin conditions?
Understanding how drugs interact with retinoic acid and vitamin D receptors at the molecular level helps scientists design better medications for psoriasis, eczema, and other skin conditions. This research provides a framework for predicting drug behavior before testing, potentially accelerating development of more effective treatments with fewer side effects.
Can this research help develop better drugs for my condition?
This foundational research provides insights that pharmaceutical companies can use to design more selective drugs targeting these receptors. If validated, it could lead to new treatment options in 5-10 years. Current medications won’t change immediately, but this knowledge may improve future drug development.
What’s the difference between how tightly a drug sticks and how well it works?
A drug that sticks very tightly might still block a receptor instead of activating it, depending on how it reshapes the protein and influences surrounding molecular interactions. This research shows that binding strength alone doesn’t predict function—the energy patterns and structural changes matter equally.
Is this study based on real patients or just computer models?
This is a computational chemistry study using computer simulations and laboratory-analyzed crystal structures, not research involving human patients or animals. While the findings are mechanistically sound, they require validation in living cells and organisms before changing medical practice.
Want to Apply This Research?
- For users managing skin conditions or immune disorders: Track symptom severity (rash coverage, itching intensity on a 1-10 scale) weekly, and note any changes after starting new medications. This creates a personal baseline for comparing how well different treatments work for your specific situation.
- When discussing treatment options with your doctor, ask whether they’re using the latest understanding of how these drugs work at the molecular level. As new drugs based on this research become available, you could work with your healthcare provider to identify which might be most effective for your condition based on your individual response patterns.
- Maintain a symptom diary tracking skin condition, energy levels, and any side effects over months and years. This long-term data helps you and your doctor identify which medications work best for you and whether newer drugs (developed using this research) offer improvements over current options.
This research describes the molecular mechanisms of how certain drugs interact with cellular receptors. It is foundational scientific research that does not directly change current medical treatment recommendations. Patients should not modify their medications based on this study. Always consult with a healthcare provider before starting, stopping, or changing any medication. This research may inform future drug development but requires extensive additional testing before new treatments become available. The findings are based on computational simulations and isolated protein structures, not studies in living organisms, so real-world applicability requires further validation.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.